Related Experiment Videos
Sextant prostate biopsies. A histopathologic correlation with radical prostatectomy specimens
P A Peller1, D C Young, D P Marmaduke
1Division of Urology, Ohio State University Medical Center, Columbus.
Cancer
|January 15, 1995
Summary
The number of positive sextant biopsies accurately predicts prostate cancer's pathologic stage and tumor volume. This aids in selecting appropriate treatment strategies for patients with localized prostate cancer.
Area of Science:
- Urology
- Oncology
- Pathology
Background:
- Preoperative prediction of tumor volume and pathologic stage in localized prostate cancer remains challenging.
- Transrectal ultrasound-guided sextant biopsies are utilized for disease assessment.
Purpose of the Study:
- To evaluate the efficacy of transrectal ultrasound-guided sextant biopsies in predicting prostate cancer tumor volume and pathologic stage.
- To identify key predictors of disease extent in patients with clinically localized prostate cancer.
Main Methods:
- Systematic sextant biopsies were performed on 102 patients with clinically resectable prostate cancer.
- Radical prostatectomy specimens were analyzed for tumor volume and stage.
- Statistical analysis, including stepwise logistic regression, compared biopsy results with various prognostic factors.
Main Results:
- The number of positive sextant biopsies significantly correlated with preoperative prostate-specific antigen (PSA), tumor volume, pathologic stage, Gleason score, and seminal vesicle involvement.
- Four or more positive biopsies and high Gleason score predicted a higher likelihood of pT3 classification.
- The number of positive biopsies and PSA levels predicted smaller tumor volumes (<0.5 ml), while biopsy count alone predicted larger tumor volumes (>4.0 ml).
Conclusions:
- The number of positive sextant biopsies is a crucial prognostic indicator for predicting pathologic (pT) classification and tumor volume in prostate cancer.
- This predictive information is valuable for optimizing treatment selection in prostate cancer management.